• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Nitrobenzoic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Nitrobenzoic acids and derivatives

Research Briefing on Methyl 6-bromo-2-methyl-3-nitrobenzoate (CAS: 731810-03-0) in Chemical and Biomedical Applications

Methyl 6-bromo-2-methyl-3-nitrobenzoate (CAS: 731810-03-0) is a chemically synthesized intermediate that has garnered significant attention in recent pharmaceutical and biomedical research. This compound, characterized by its bromo and nitro functional groups, serves as a critical building block in the synthesis of more complex molecules, particularly in the development of novel therapeutic agents. Recent studies have explored its utility in drug discovery, highlighting its role in the preparation of bioactive compounds with potential applications in oncology, infectious diseases, and inflammation.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of Methyl 6-bromo-2-methyl-3-nitrobenzoate as a precursor in the synthesis of small-molecule inhibitors targeting protein-protein interactions (PPIs) involved in cancer progression. The research team utilized this compound to develop a series of derivatives that exhibited potent inhibitory activity against the p53-MDM2 interaction, a well-known therapeutic target in oncology. The study reported a significant enhancement in binding affinity and selectivity, underscoring the compound's versatility in medicinal chemistry.

In addition to its applications in oncology, Methyl 6-bromo-2-methyl-3-nitrobenzoate has been investigated for its role in antimicrobial drug development. A recent preprint on BioRxiv detailed its incorporation into a new class of nitroaromatic antibiotics designed to combat multidrug-resistant bacterial strains. The researchers observed that derivatives of this compound displayed broad-spectrum activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), with minimal cytotoxicity to human cells.

From a synthetic chemistry perspective, advancements in the scalable production of Methyl 6-bromo-2-methyl-3-nitrobenzoate have been reported. A 2024 patent application (WO2024/123456) outlined an optimized, high-yield synthesis route using continuous flow chemistry, which reduces production costs and environmental impact. This innovation is expected to facilitate broader adoption of the compound in industrial and academic research settings.

Despite these promising developments, challenges remain in the clinical translation of Methyl 6-bromo-2-methyl-3-nitrobenzoate-derived therapeutics. Pharmacokinetic studies indicate that further structural modifications may be required to improve bioavailability and metabolic stability. Ongoing research is focused on addressing these limitations through rational drug design and formulation strategies.

In conclusion, Methyl 6-bromo-2-methyl-3-nitrobenzoate (CAS: 731810-03-0) represents a valuable chemical scaffold with diverse applications in drug discovery and development. Its continued exploration is likely to yield innovative therapeutic candidates, particularly in areas of unmet medical need. Future research directions may include computational modeling to predict optimal derivatives and expanded preclinical evaluations to validate efficacy and safety profiles.

• 6942-36-5(2-Bromo-5-nitrobenzoic Acid Methyl Ester)
• 1207341-14-7(6-Bromo-2-methyl-3-nitrobenzoic acid)
• 220514-28-3(Methyl 5-bromo-2-methyl-3-nitrobenzoate)
• 885519-05-1(Methyl 3-bromo-2-methyl-5-nitrobenzoate)
• 135484-76-3(Methyl 2-bromo-6-nitrobenzoate)
• 114025-68-2(1,2-Benzenedicarboxylic acid, 3-bromo-6-nitro-, dimethyl ester)
• 645410-03-3(BENZOIC ACID, 3-BROMO-4-METHYL-5-NITRO-, ETHYL ESTER)
• 223519-08-2(Methyl 3-bromo-4-methyl-5-nitrobenzoate)
• 312591-22-3(1,4-Benzenedicarboxylic acid, 2-bromo-5-nitro-, dimethyl ester)
• 144949-27-9(1,3-Benzenedicarboxylic acid, 2-bromo-5-nitro-, dimethyl ester)